Recurrent Urinary Tract Infections
Conditions
Interventions
Control group:After conventional therapy (targeted antimicrobial therapy directed against the uropathogen identified by microbiological testing), no further intervention is given.
Sponsors
Department of Infectious Diseases, First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Enrollment Criteria : Patients may choose to enter the study when they meet all of the following criteria 1. Age >=18 years old and <=80 years old, male or female; 2. No less than 3 episodes of lower urinary tract infection in the past 12 months or no less than 2 lower urinary tract infections in 6 months; 3. The most recent recurrence of lower urinary tract infection has been treated to achieve symptom resolution, and the therapeutic dose of antibiotics has been discontinued, and at least one of the following conditions is met: (1) Mid-section urine bacterial culture < 10^5 CFU/mL (after receiving the test results after the most recent improvement); (2) Urine white blood cell count < 5/HP, and if white blood cells can be measured in routine urine test, < 25/µL must be met 4. Patients or family members are able to understand the study protocol, are willing to participate in this study, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. Severe primary disecases of the cardiovascular, cerebrovascular, or hematopoietic systems. 2. Diabetes mellitus with poor glycaemic control (HbA1c > 7.5 %). 3. Genital-tract malformation, acute genital-tract infection, or genital-tract malignancy. 4. Genitourinary tuberculosis or acute pyelonephritis. 5. Vesico-ureteric reflux or urinary diversion. 6. Polycystic kidney disease, neurogenic bladder, indwelling catheter, or any obstructive uropathy deemed by the investigator to be caused by urinary stones, tumour, or fibrosis. 7. eGFR 1.5 × ULN, AST or ALT > 2 × ULN). 9. Use of immunosuppressive agents or systemic corticosteroids > 10 mg/day. 10. Receipt of any investigational drug or participation in another interventional clinical trial within 30 days before screening. 11. History of alcohol or drug abuse, or psychiatric disorder that could compromise compliance. 12. Any condition that, in the opinion of the investigator, renders the subject unsuitable for enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal 16s rDNA sequencing results;Recurrence time and number of treatments; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological indicators;Metabolite characteristics;Proteomic characteristics; | — |
Countries
China
Contacts
Public ContactJiabin Li
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed